Bio-Rad Laboratories's total revenue is $2.6B, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
The latest total revenue for BIO is $2.6B as of June 2026. That compares with $2.6B in the prior-year period — up 1.4% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Bio-Rad Laboratories's historical trend and sector peers before judging valuation or financial health.
Over the past year, BIO's total revenue moved from $2.6B to $2.6B — a 1.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bio-Rad Laboratories's operating scale or balance-sheet position.
Against Healthcare companies, BIO currently prints $2.6B for total revenue, while the sector average sits near $110B. That is roughly 97.7% below the sector mean. Large gaps often invite a closer look at Bio-Rad Laboratories's growth, margins, and balance sheet.
A total revenue figure of $2.6B for BIO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.
After noting BIO's total revenue ($2.6B), review year-over-year change from $2.6B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.